ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO497

Etelcalcetide Use Affects Changes in Agatston Coronary Artery Calcium (CAC) Score in Maintenance Dialysis Patients

Session Information

Category: Hypertension and CVD

  • 1602 Hypertension and CVD: Clinical


  • Doi, Toshiki, Ichiyokai Harada Hospital, Hiroshima, Japan
  • Morii, Kenichi, Ichiyokai Harada Hospital, Hiroshima, Japan
  • Mizuiri, Sonoo, Ichiyokai Harada Hospital, Hiroshima, Japan
  • Nishizawa, Yoshiko, Ichiyokai Harada Hospital, Hiroshima, Japan
  • Masaki, Takao, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan

Dialysis patients are known to be at high cardiovascular risk, and the Agatston CAC score, a measure of coronary artery calcification, has been associated with cardiovascular events. Recently, calcimimetics such as etelcalcetide have been used to manage secondary hyperparathyroidism, but their effect on vascular calcification is unknown. Therefore, the present study investigated whether etelcalcetide use affects changes in Agatston CAC scores in maintenance hemodialysis patients.


This historical cohort study included 192 patients undergoing maintenance hemodialysis who had Agatston CAC score of 100 or higher and were not using calcimimetics other than etelcalcetide. Propensity score matching was performed by age, gender, diabetes mellitus, Ca, iP, and intact PTH. In addition, we examined whether there was a difference in etelcalcetide use and the rate of change in Agatston CAC score after one year.


In the two groups of patients matched for background factors by propensity scores (18 patients each), the Agatston CAC score change was significantly lower in the etelcalcetide use group (p = 0.0284).


Etelcalcetide use in maintenance dialysis patients may reduce coronary calcification.